Related Experiment Video

Updated: Aug 16, 2026

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia
09:36

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia

Published on: December 22, 2023

Ryanodine receptor-targeted anti-arrhythmic therapy

Xander H T Wehrens1, Stephan E Lehnart, Andrew R Marks

  • 1Department of Physiology and Cellular Biophysics, Center for Molecular Cardiology, College of Physicians and Surgeons of Columbia University, New York, New York 10032, USA.

Annals of the New York Academy of Sciences
|August 12, 2005
PubMed

Insights

Altered calcium handling in heart failure and CPVT causes fatal arrhythmias. New therapies target defective calcium release from the sarcoplasmic reticulum to prevent sudden cardiac death.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Genetics

Background:

  • Cardiac arrhythmias, particularly in heart failure (HF) and inherited syndromes like catecholaminergic polymorphic ventricular tachycardia (CPVT), are significant causes of mortality.
  • Intracellular calcium handling is critical in the development of cardiac arrhythmias.

Purpose of the Study:

  • To investigate the role of sarcoplasmic reticulum (SR) calcium leak via cardiac ryanodine receptors (RyR2) in HF and CPVT-related arrhythmias.
  • To explore novel therapeutic strategies targeting SR Ca(2+) release defects.

Main Methods:

  • Analysis of intracellular calcium handling mechanisms in cardiac cells.
  • Investigation of RyR2 function in models of heart failure and CPVT.
  • Evaluation of potential therapeutic interventions.

Main Results:

  • Diastolic calcium leak from the SR through RyR2 can trigger delayed afterdepolarizations and arrhythmias in HF.
  • Mutant RyR2 channels causing SR Ca(2+) leak are implicated in exercise-induced arrhythmias in CPVT patients.
  • Understanding these Ca(2+) leak mechanisms provides a basis for new therapeutic approaches.

Conclusions:

  • Defective SR Ca(2+) release, specifically SR Ca(2+) leak via RyR2, is a key mechanism in life-threatening arrhythmias in HF and CPVT.
  • Targeting these calcium handling abnormalities offers a promising therapeutic avenue for preventing sudden cardiac death in these conditions.

More Related Videos

Advanced Cardiac Rhythm Management by Applying Optogenetic Multi-Site Photostimulation in Murine Hearts08:43

Advanced Cardiac Rhythm Management by Applying Optogenetic Multi-Site Photostimulation in Murine Hearts

Published on: August 26, 2021

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...